The major factors boosting the growth of breast pumps market are increasing working women population, rise in disposable income and growing awareness about importance of breastfeeding. In terms of revenue, closed system breast pumps segment accounted for major share in the world breast pumps market in 2015, and is projected to maintain this trend throughout the forecast period, growing at a faster CAGR of over 6%.
Breast pumps refer to the mechanical device that helps to draw milk from the women’s breast by suction. These devices are regulated by the U.S. Food and Drug Administration. Breast pump are the supplement of the breastfeeding and operated technologies such as electric, battery powered and manual.
Breast biopsy is a diagnostic procedure used involves the removal of sample from breast tissue for laboratory testing to determine the presence of cancerous cells. Biopsy is an initial test suggesting the area of tissue in the body not seems to be normal. There are different type of breast biopsy procedures performed in market which includes fine-needle aspiration, hollow or core needle and biopsy with vacuum-powered device. During breast biopsy, the test results are evaluated whether the suspicion area is cancerous or benign, and respective decision is taken regarding its treatment. Over the past few years screening and diagnostic market has improved and has eliminated the need for excisional biopsy to obtain a diagnosis of breast cancer.
According to QYR study, the Global revenue of Breast Implants was valued at 1193.33 M USD in 2017, and is forecast to reach 1681.49 M USD by the end of 2023. Global giant manufactures mainly distributed in America and Europe. They have unshakable status in this field. The key product markets locate at America and Europe.
The digital breast tomosynthesis (DBT) system is used to create a 3-dimentional image of breast by using many low/high dose x-rays obtained at different angles. Digital breast tomosynthesis is similar to computed tomography imaging in which a number of images is taken to create a 3-D image of body. Mostly digital breast tomosynthesis used low dose of radiation, but for some procedures, digital breast tomosynthesis have higher level of radiation dose than that of standard mammography. Although, radiation dose remains within the criteria of safe dose levels of radiation as per the regulations. According to GLOBOCAN, 1.7 million cases of breast cancer were diagnosed worldwide in 2012. Incidence of breast cancer is increasing worldwide, and so the number of deaths due to breast cancer. Digital breast tomosynthesis helps to identify the breast cancers that cannot be identified with conventional mammography.
Automated breast ultrasound system is particularly developed for entire breast imaging. The report provides detailed segmentation of the automated breast ultrasound system market based on end-user and region.
Big Market Research, Global PharmaPoint HER2-Positive Breast Cancer Drug Market Size, Share, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities, Segmentation, to 2023. Browse complete report & TOC @ http://www.bigmarketresearch.com/pharmapoint-her2-positive-breast-cancer-global-drug-forecast-and-analysis-to-2023-market
HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic. This report forecasts that the two monoclonal antibodies that also target the HER2 receptor will ensure Roche still occupies over 95% of the market in 2023. The challenge for new entrants into the HER2-positive market is to find patient populations that are currently underserved, and can work cooperatively with Roche’s targeted therapies. The HER2-positive breast cancer market will increase by 2.5-fold, reaching $12.63bn by 2023, at a CAGR of 9.82%, driven by the rapid uptake of the latest premium-priced biologics.
By 2023, the largest market segment will be the adjuvant setting, with rapid growth at a CAGR of 12.3%, and representing 63% of the total HER2-positive market. Herceptin will no longer be the market leader, with new agents Perjeta and Kadcyla taking 37% and 39% market share respectively.